COVID-19 People's Vaccine

Why the HIV Community can make a difference

or many years the prohibitive prices of HIV medicines meant only the world’s wealthiest countries and people could afford them. While in the global north effective treatment was widely available from 1996 onwards, in low- and middle-income countries people continued to die in their millions. This is largely because pharmaceutical companies were unwilling to relinquish the monopolies granted to them under intellectual property rules to allow low-cost production of generic versions of their products.

Download pdf

We use cookies to give you the best possible experience on our website. By clicking OK, you agree to our cookie policy. OK